PharmaCyte Biotech, Inc.

- 28 AUG 2019
PharmaCyte Biotech Confirms Dr. Manuel Hidalgo Will Be Principal Investigator for Clinical Trial in Pancreatic Cancer
LAGUNA HILLS, CA, August 28, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that nationally and internationally renowned clinician and oncologist, Dr. Manuel Hidalgo, has confirmed that he will be
Read more →
- Posted in
- News
- 27 AUG 2019
PharmaCyte Biotech Releases Proxy Statement Related to Special Shareholder Meeting
LAGUNA HILLS, CA, August 27, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its proxy statement related to the announced Special Shareholder Meeting on September 11, 2019, is available
Read more →
- Posted in
- News
- 21 AUG 2019
PharmaCyte Biotech to Hold Special Shareholder Meeting
LAGUNA HILLS, CA–(BUSINESS WIRE)—August 21, 2019 – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019. The shareholder meeting, not to be
Read more →
- Posted in
- News
- 22 JUL 2019
PharmaCyte Biotech and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes
LAGUNA HILLS, CA, July 22, 2019 (BUSINESS WIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a new research agreement with the University of Technology Sydney
Read more →
- Posted in
- News
- 15 JUL 2019
PharmaCyte Biotech Appoints Cellular Expert to Medical and Scientific Advisory Board
LAGUNA HILLS, Calif.–(BUSINESS WIRE)—July 15, 2019 – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed David A. Judd to PharmaCyte’s Medical and
Read more →
- Posted in
- News
- 25 JUN 2019
PharmaCyte Biotech Releases New Interviews from Austrianova’s GMP Facility on Company’s Website
LAGUNA HILLS, CA, June 25, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, remains in Bangkok, Thailand, during the GMP-manufacturing
Read more →
- Posted in
- News
- 10 JUN 2019
PharmaCyte Biotech CEO In Thailand to Oversee Production of Final Clinical Trial Material for IND Submission
LAGUNA HILLS, CA, JUNE 10, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, and
Read more →
- Posted in
- News
- 03 JUN 2019
PharmaCyte Biotech CEO Visiting GMP Facility with Cellular Biology Consultant During Production of Pancreatic Cancer Product
LAGUNA HILLS, CA, JUNE 3, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, and
Read more →
- Posted in
- News
- 20 MAY 2019
PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
LAGUNA HILLS, CA, May 20, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has made further important progress in optimizing the complete manufacturing process, including significant
Read more →
- Posted in
- News
- 13 MAY 2019
PharmaCyte Biotech Bioengineers Cell Line for Cannabis Program to Treat Cancers
LAGUNA HILLS, CA, May 13, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado, has bioengineered
Read more →
- Posted in
- News

Press Releases